» Articles » PMID: 31488880

In Utero Exposure to Breast Cancer Treatment: a Population-based Perinatal Outcome Study

Overview
Journal Br J Cancer
Specialty Oncology
Date 2019 Sep 7
PMID 31488880
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.

Citing Articles

Pregnancy associated cancer, timing of birth and clinical decision making-a NSW data linkage study.

Safi N, Li Z, Anazodo A, Remond M, Hayen A, Currow D BMC Pregnancy Childbirth. 2023; 23(1):105.

PMID: 36759774 PMC: 9909861. DOI: 10.1186/s12884-023-05359-1.


Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.

Triarico S, Rivetti S, Capozza M, Romano A, Maurizi P, Mastrangelo S Cancers (Basel). 2022; 14(13).

PMID: 35804875 PMC: 9264939. DOI: 10.3390/cancers14133103.


Trastuzumab administration during pregnancy: an update.

Andrikopoulou A, Apostolidou K, Chatzinikolaou S, Bletsa G, Zografos E, Dimopoulos M BMC Cancer. 2021; 21(1):463.

PMID: 33902516 PMC: 8074427. DOI: 10.1186/s12885-021-08162-3.


Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents.

Benoit L, Mir O, Vialard F, Berveiller P Cancers (Basel). 2021; 13(6).

PMID: 33799824 PMC: 8000411. DOI: 10.3390/cancers13061238.


Update on the Management of Breast Cancer during Pregnancy.

Poggio F, Tagliamento M, Pirrone C, Soldato D, Conte B, Molinelli C Cancers (Basel). 2020; 12(12).

PMID: 33287242 PMC: 7761659. DOI: 10.3390/cancers12123616.

References
1.
Albright C, Wenstrom K . Malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015; 33:2-18. DOI: 10.1016/j.bpobgyn.2015.10.004. View

2.
Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska M, Boere I . Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2015; 373(19):1824-34. DOI: 10.1056/NEJMoa1508913. View

3.
Loibl S, Han S, von Minckwitz G, Bontenbal M, Ring A, Giermek J . Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012; 13(9):887-96. DOI: 10.1016/S1470-2045(12)70261-9. View

4.
Shachar S, Gallagher K, McGuire K, Zagar T, Faso A, Muss H . Multidisciplinary Management of Breast Cancer During Pregnancy. Oncologist. 2017; 22(3):324-334. PMC: 5344634. DOI: 10.1634/theoncologist.2016-0208. View

5.
Morice P, Uzan C, Uzan S . Cancer in pregnancy: a challenging conflict of interest. Lancet. 2012; 379(9815):495-6. DOI: 10.1016/S0140-6736(11)61814-X. View